

Tripp, et al.  
Application No. 10/532,388  
from International Application No. PCT/US03/033362  
I.A. filing date: October 20, 2003

RECEIVED  
CENTRAL FAX CENTER

JUN 21 2007

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-235 (PREVIOUSLY CANCELED).

236. (CURRENTLY AMENDED) A composition comprising as a first component selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone, a fraction isolated or derived from hops; and as a second component, at least one member selected from the group consisting of rosemary, an extract derived from rosemary, a compound derived from rosemary, and a triterpene species.

237. (CANCELED) The composition of Claim 236, wherein the fraction isolated or derived from hops is extracted with CO<sub>2</sub>.

238. (CURRENTLY AMENDED) The composition of Claim 236, wherein the first component selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone is fraction isolated or derived from hops is reduced isocalpha acids.

239. (CANCELLED) The composition of Claim 236, wherein the fraction isolated or derived from hops comprises a compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.

Tripp, et al.  
Application No. 10/532,388  
from International Application No. PCT/US03/033362  
I.A. filing date: October 20, 2003

240. (PREVIOUSLY PRESENTED) The composition of Claim 236, wherein the second component is a compound derived from rosemary selected from the group consisting of 1,8-cineole, 19-alpha-hydroxyursolic acid, 2- $\beta$ -hydroxyoleanolic acid, 3-O-acetyloleanolic acid, 3-O-acetylursolic acid, 6-methoxy-luteolin-7-glucoside, 6-methoxyluteolin, 6-methoxyluteolin-7-glucoside, methoxyluteolin-7-methylether, 7-ethoxy-rosmanol, 7-methoxy-rosmanol, alpha-amyrin, alpha-humulene, alpha-hydroxyhydrocaffelc acid, alpha-pinene, alpha-terpinene, alpha-terpinenyl acetate, alpha-terpineol, alpha-thujone, apigenin, apigenin-7-glucoside, curcumene, benzyl-alcohol,  $\beta$ -amyrenone,  $\beta$ -amyrin,  $\beta$ -elemene,  $\beta$ -pinene, betulin, betulinic acid, borneol, bornyl-acetate, caffeic acid, camphene, camphor, carnosic acid, carnosol, carvacrol, carvone, caryophyllene, caryophyllene-oxide, chlorogenic acid, diosmetin, gamma-terpinene, hesperidin, isoborneol, limonene, luteolin, luteolin-3'-O-(3"-O-acetyl)- $\beta$ -D-glucuronide, luteolin-3'-O-(4"-O-acetyl)- $\beta$ -D-glucuronide, luteolin-3'-O- $\beta$ -D-glucuronide, luteolin-7-glucoside, methyl-eugenol, myrcene, neo-chlorogenic acid, nepetin, octanoic acid, oleanolic acid, p-cymene, piperitenone, rosmanol, rosmarinic acid, rosmarinic acid, rosmaridiphenol, rosmarinic acid, rosmarinol, rosmarinquinone, sabinene, sabinal acetate, salicylates, salicylic acid-2- $\beta$ -D-glucoside, squalene, terpinen-4-ol, terpinolene, thymol, trans-anethole, trans-carveol, ursolic acid, verbenone, and zingiberene.

241. (PREVIOUSLY PRESENTED) The composition of Claim 236, wherein the second component is a triterpene species selected from the group consisting of 18-a-glycyrrhetic acid, 18- $\beta$ -glycyrrhetic acid, 2-a-3-a-dihydroxyurs-12-3n-28-onic acid, 3-a-hydroxyursolic acid, 3-oxo-ursolic acid, betulin, betulinic acid, celastrol, eburicoic acid, friedelin, glycyrrhizin, gypsogenin, oleanolic acid, oleanolic acid-3-acetate, pachymic acid, pinicolic acid, sophoradiol, soyasapogenol A, soyasapogenol B, tripterin, triptophenolide, tumulosic acid, ursolic acid, ursolic acid-3-acetate, uvaol, and  $\beta$ -sitosterol.

242. (CURRENTLY AMENDED) The composition of Claim 236, wherein the composition comprises about 0.5 to 10,000 mg of the first component-fraction isolated or derived from hops.

Tripp, et al.  
Application No. 10/532,388  
from International Application No. PCT/US03/033362  
I.A. filing date: October 20, 2003

243. (PREVIOUSLY PRESENTED) The composition of Claim 236, wherein the composition comprises about 0.5 to 5,000 mg of the second component, wherein the second component is selected from the group consisting of rosemary, extract derived from rosemary, and a compound derived from rosemary.

244. (PREVIOUSLY PRESENTED) The composition of Claim 236, wherein the composition comprises about 0.035 to 3,500 mg of a triterpene species, wherein the second component is a triterpene species.

245. (PREVIOUSLY PRESENTED) The composition of Claim 236, wherein the composition comprises about 0.001 to 10 weight percent of the first component.

246. (PREVIOUSLY PRESENTED) The composition of Claim 236, wherein the composition comprises about 0.001 to 10 weight percent of the second component.

247. (PREVIOUSLY PRESENTED) The composition of Claim 236, wherein a ratio of the first component to the second component is in the range of about 100:1 to about 1:100.

248. (PREVIOUSLY PRESENTED) The composition of Claim 236, wherein the composition further comprises a pharmaceutically acceptable carrier.

249. (PREVIOUSLY PRESENTED) The composition of claim 236, further comprising glucosamine.

250. (PREVIOUSLY PRESENTED) A method of modulating inflammatory response in cells, the method comprising contacting the cells with a composition comprising a fraction isolated or derived from hops and a second component selected from the group consisting of rosemary, an extract derived from rosemary, a compound derived from rosemary, and a triterpene species.

251. (PREVIOUSLY PRESENTED) The method of claim 250, wherein the composition further comprises glucosamine.

Tripp, et al.  
Application No. 10/532,388  
from International Application No. PCT/US03/033362  
I.A. filing date: October 20, 2003

252. (CURRENTLY AMENDED) A method of treating or inhibiting a pathological condition in a mammal associated with tissue-specific activation of inflammation, the method comprising administering to the mammal a composition comprising a first component selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone; fraction isolated or derived from hops and a second component selected from the group consisting of rosemary, an extract derived from rosemary, a compound derived from rosemary, and a triterpene species.

253. (CURRENTLY AMENDED) The method of Claim 252, wherein the composition comprises about 0.5 to 10000 mg of the first component fraction isolated or derived from hops.

254. (CURRENTLY AMENDED) The method of Claim 252, wherein the composition comprises about 0.001 to 10 weight percent of the first component fraction isolated or derived from hops.

255. (PREVIOUSLY PRESENTED) The method of Claim 252, wherein the composition further comprises a third component different from the second component, said third component is selected from the group consisting of rosemary, an extract derived from rosemary, a compound derived from rosemary, and a triterpene species.

256. (NEW) The method of claim 252, wherein the first component selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone is derived from hops.